Minophagen acquires Japanese rights to Eisai's bexarotene
This article was originally published in Scrip
Eisai has sublicensed exclusive Japanese development and commercialisation rights to its oncology product bexarotene to Minophagen Pharmaceutical, retaining an option to co-promote the retinoid molecule in this market as part of the deal.
You may also be interested in...
First-line lung cancer approval will expand potential market for Takeda's ALK contender but the latecomer is also facing some well-established class competition in the setting.
US venture raises new funds from Asia partners as it builds a direct presence in China to develop its oncology portfolio.
Novartis gene therapy gets insurance coverage at record price although small patient population will limit system costs.